Glaukos (NYSE:GKOS) Sets New 52-Week High on Earnings Beat

Glaukos Corporation (NYSE:GKOS) reached a new 52-week high on Thursday following a stronger than expected earnings report. The company traded as high as $166.00 and last traded at $161.9730, with a volume of 3136767 shares traded. The stock had previously closed at $151.33.

The medical instruments supplier reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to the consensus estimate of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.Glaukos’s quarterly revenue was up 49.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.24) earnings per share.

Glaukos News Summary

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Quarterly results exceeded expectations. Glaukos reported second-quarter revenue of $185.6 million, up 49.6% year over year and well above the $150.9 million consensus estimate. Its adjusted loss of $0.14 per share was narrower than the expected $0.21 loss, supported by growth in iDose TR and Epioxa. Glaukos Q2 Earnings Beat Estimates on iDose TR Growth
• Positive Sentiment: Management raised its 2026 outlook. Glaukos now expects net sales of $680 million to $700 million, with iDose TR revenue projected at $275 million to $280 million. The higher forecast signals continued commercial momentum and was a key reason the stock advanced. Glaukos outlines 2026 sales outlook
• Positive Sentiment: Clinical and analyst catalysts added support. The company reported progress on its PRESERFLO study, while BTIG raised its price target from $164 to $193 and maintained a Buy rating. BTIG raises Glaukos price target
• Neutral Sentiment: UBS Group initiated coverage of Glaukos, potentially broadening institutional attention, although the available report does not provide a detailed rating or price target. UBS initiates Glaukos coverage
• Negative Sentiment: Valuation and profitability remain risks. Despite the improved results, Glaukos remains unprofitable, and commentary questioned whether the stock’s strong rally has priced in much of its growth potential. Future gains may depend on continued iDose TR adoption and execution against the raised forecast. Glaukos record sales and valuation analysis

Analyst Ratings Changes

A number of brokerages recently commented on GKOS. William Blair reissued an “outperform” rating on shares of Glaukos in a research note on Tuesday, May 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a research report on Friday, July 17th. Wells Fargo & Company upped their price target on shares of Glaukos from $138.00 to $178.00 and gave the company an “overweight” rating in a report on Thursday. BTIG Research increased their price target on shares of Glaukos from $164.00 to $193.00 and gave the company a “buy” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. raised their price objective on shares of Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Twelve analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $177.33.

Insider Transactions at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 5,000 shares of the firm’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $140.76, for a total transaction of $703,800.00. Following the sale, the director directly owned 35,528 shares of the company’s stock, valued at $5,000,921.28. This trade represents a 12.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alex R. Thurman sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, July 16th. The shares were sold at an average price of $160.00, for a total transaction of $1,600,000.00. Following the completion of the transaction, the chief financial officer directly owned 43,906 shares of the company’s stock, valued at approximately $7,024,960. This represents a 18.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 40,000 shares of company stock worth $6,028,800. 5.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. First Horizon Corp grew its position in shares of Glaukos by 1,715.4% in the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 223 shares during the period. Los Angeles Capital Management LLC purchased a new position in Glaukos during the fourth quarter worth about $28,000. Larson Financial Group LLC lifted its position in Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 132 shares during the period. Parallel Advisors LLC boosted its stake in Glaukos by 159.2% in the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 226 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in Glaukos by 111.4% in the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 215 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Stock Down 1.2%

The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.04. The company has a market cap of $9.82 billion, a PE ratio of -51.24 and a beta of 0.75. The firm has a fifty day simple moving average of $138.11 and a 200 day simple moving average of $125.07.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.